Clinical trials: Neoplasms, Pharyngeal
Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
The goal of this clinical research study is to compare the use of MRI simulations to plan different doses of intensity modulated radiotherapy (IMRT) to the standard IMRT dose in patients with low risk human papilloma virus…
- Trial name
- NCT03224000
- Testing
- Modified Barium Swallow (MBS), Swallowing Questionnaire, Symptom Questionnaire
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC
Patients have a type of cancer called nasopharyngeal cancer. This cancer has come back or not gone away or is at high risk for coming back after treatment (including the best treatment we know for nasopharyngeal cancer).
- Trial name
- NPC (NCT00609219)
- Testing
- autologous EBV specific CTLs
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
Wilms Tumor, Fibrosarcoma
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.
- Conditions
- Wilms Tumor, Fibrosarcoma, Carcinoma, Round Cell, Nasopharyngeal Cancer
- Trial name
- NCT00141765
- Testing
- Myeloablative Chemotherapy, Stem Cell Rescue
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.
- Conditions
- Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect
- Trial name
- NCT04586088
- Testing
- Apatinib plus Camrelizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC), EBV
KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial
The main purpse of this study is to evaluate the safety of KSD-101 in patients with EBV-associated Nasopharyngeal Carcinoma,to evaluate the initial clinical outcomes and evaluate the immune response to KSD-101 for the treatment…
- Trial name
- NCT06752473
- Testing
- KSD-101
- Volunteers
- 10 people
- Sponsor
- Kousai Bio Co., Ltd.
Malignant Neoplasm of Other Specified Site of Nasopharynx
Retrospective Investigation of the Impacts of Prognosis for Nasopharyngeal Carcinoma Patients
To investigate whether the additional induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) was able to improve overall survival (OS) and disease-free survival (DFS), and to clarify if stage-specified…
- Trial name
- NCT02604472
- Testing
- CCRT, IC+CCRT
- Volunteers
- 12,206 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Oral Cavity Cancer
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate if the addition of valproic acid to standard platinum-based chemoradiation as definitive treatment of locally advanced Head and Neck squamous cell carcinoma can improve treatment outcomes…
- Conditions
- Head and Neck Cancer, Oral Cavity Cancer, Oropharyngeal Cancer
- Trial name
- NCT01695122
- Testing
- Valproic Acid
- Where
- Brazil
- Volunteers
- 14 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with…
- Trial name
- NCT06892431
- Testing
- Mitoxantrone Hydrochloride Liposome, JMT101 injection, Capecitabine
- Volunteers
- 150 people
- Sponsor
- Shanghai JMT-Bio Inc.
Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
This is a phase II clinical trial. The purpose of this study is to determine the feasibility of deescalating chemoradiation treatment based on mid-treatment tumor response determined by rapid nodal shrinkage and clearance of…
- Trial name
- NCT03215719
- Testing
- Standard Radiation Treatment, Dose-Deescalated Treatment, Cisplatinum
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- NYU Langone Health
Head and Neck Cancer, Cervical Cancer
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05955105
- Testing
- ILB-2109, Toripalimab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Innolake Biopharm
Nasopharyngeal Cancinoma (NPC)
Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC
This Phase III multicenter trial investigates treatment intensification for high-risk, stage T1-2N1M0 nasopharyngeal carcinoma. Patients with high-risk features (>3 metastatic lymph nodes, necrosis, or confluence) receive…
- Trial name
- NCT07248670
- Testing
- metronomic adjuvant chemotherapy with capecitabine
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Chongqing University Cancer Hospital
Oral Cancer, Oropharyngeal Cancer
uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer
uPAR PET/CT for Staging Advanced and Localised oral and oropharyngeal cancer
- Conditions
- Oral Cancer, Oropharyngeal Cancer, Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT02960724
- Testing
- 68Ga-NOTA-AE105 PET/CT
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Oropharyngeal Neoplasms
Isocapnic Hyperventilation - an Alternative Method
Isocapnic hyperventilation (IHV) is a method that shortens time to extubation after inhalation anaesthesia by increasing airway carbon dioxide (CO2) during hyperventilation (HV).
- Trial name
- NCT03074110
- Testing
- Isocapnic hyperventilation
- Where
- Sweden
- Volunteers
- 31 people
- Sponsor
- Sahlgrenska University Hospital
Head-and-neck Squamous Cell Carcinoma
De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas
In patients with squamous cell carcinoma of the oral cavity, the oropharynx and larynx with local advanced tumors (pathologic stage T3 = pT3) and or lymph node involvement (pN+) postoperative radio - or radiochemotherapy is the…
- Trial name
- DELPHI (NCT03396718)
- Testing
- De-escalation radio(chemo)therapy - Level 1, De-escalation radio(chemo)therapy - Level 2, Standard radio(chemotherapy)
- Where
- 10 sites in Germany
- Volunteers
- 304 people
- Sponsor
- Technische Universität Dresden
Nasopharyngeal Carcinoma
NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
By this clinical trial, the investigators are trying to give an answer to such a question. Whether NPC patients staged N2-3M0 need adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation?
- Trial name
- NCT01694576
- Testing
- Adjuvant chemotherapy with paclitaxel and nedaplatin
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Nasopharyngeal Carcinoma, PET/MR
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT03657017
- Testing
- PET/MR
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes
Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients
Preoperative Immune checkpoint inhibitors combined with chemotherapy have revolutionized the treatment landscape of locally advanced esophageal squamous cell carcinoma.
- Conditions
- Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes, Immunotherapy
- Trial name
- PICCRT (NCT05596890)
- Testing
- Paclitaxel-albumin, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangdong Provincial People's Hospital
Nasopharyngeal Carcinoma
Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPC
PET/CT and EBV DNA are important in diagnosis of NPC. We consider that combining post-treament PET/CT and plasma EBV DNA may be effective in evaluating the hazard of progression in the follow-up of Locally Advanced Nasopharyngeal…
- Trial name
- NCT03601390
- Testing
- PET/CT and EBV DNA
- Where
- China
- Volunteers
- 387 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma by AJCC V8 Stage
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT05717790
- Testing
- Nimotuzumab, Gemcitabine, Cisplatin
- Where
- 9 sites in China
- Volunteers
- 288 people
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
Kaposi´s Sarcoma
Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi sarcoma remains the most common malignancy among persons with HIV. Lesions localized to the airway may cause bleeding, pain and dyspnea. New therapeutic approaches for local disease are needed.
- Trial name
- NCT01296815
- Testing
- Bevacizumab
- Where
- Mexico
- Volunteers
- 14 people
- Sponsor
- Centro de Investigación en. Enfermedades Infecciosas, Mexico
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.